Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden</title><author><name sortKey="Kataoka, Yu" sort="Kataoka, Yu" uniqKey="Kataoka Y" first="Yu" last="Kataoka">Yu Kataoka</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Andrews, Jordan" sort="Andrews, Jordan" uniqKey="Andrews J" first="Jordan" last="Andrews">Jordan Andrews</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Duong, Myngan" sort="Duong, Myngan" uniqKey="Duong M" first="Myngan" last="Duong">Myngan Duong</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Nguyen, Tracy" sort="Nguyen, Tracy" uniqKey="Nguyen T" first="Tracy" last="Nguyen">Tracy Nguyen</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Schwarz, Nisha" sort="Schwarz, Nisha" uniqKey="Schwarz N" first="Nisha" last="Schwarz">Nisha Schwarz</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Fendler, Jessica" sort="Fendler, Jessica" uniqKey="Fendler J" first="Jessica" last="Fendler">Jessica Fendler</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Puri, Rishi" sort="Puri, Rishi" uniqKey="Puri R" first="Rishi" last="Puri">Rishi Puri</name><affiliation><nlm:aff id="aff2">Department of Cardiovascular Medicine,<institution>Cleveland Clinic</institution>,<addr-line>Cleveland, Ohio</addr-line>,<country>USA</country>;</nlm:aff></affiliation></author><author><name sortKey="Butters, Julie" sort="Butters, Julie" uniqKey="Butters J" first="Julie" last="Butters">Julie Butters</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Keyserling, Constance" sort="Keyserling, Constance" uniqKey="Keyserling C" first="Constance" last="Keyserling">Constance Keyserling</name><affiliation><nlm:aff id="aff3">Cerenis Therapeutics SA, Labege,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Paolini, John F" sort="Paolini, John F" uniqKey="Paolini J" first="John F." last="Paolini">John F. Paolini</name><affiliation><nlm:aff id="aff3">Cerenis Therapeutics SA, Labege,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Dasseux, Jean Louis" sort="Dasseux, Jean Louis" uniqKey="Dasseux J" first="Jean-Louis" last="Dasseux">Jean-Louis Dasseux</name><affiliation><nlm:aff id="aff3">Cerenis Therapeutics SA, Labege,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Nicholls, Stephen J" sort="Nicholls, Stephen J" uniqKey="Nicholls S" first="Stephen J." last="Nicholls">Stephen J. Nicholls</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28567351</idno><idno type="pmc">5440269</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440269</idno><idno type="RBID">PMC:5440269</idno><idno type="doi">10.21037/cdt.2017.02.01</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">001824</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001824</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden</title><author><name sortKey="Kataoka, Yu" sort="Kataoka, Yu" uniqKey="Kataoka Y" first="Yu" last="Kataoka">Yu Kataoka</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Andrews, Jordan" sort="Andrews, Jordan" uniqKey="Andrews J" first="Jordan" last="Andrews">Jordan Andrews</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Duong, Myngan" sort="Duong, Myngan" uniqKey="Duong M" first="Myngan" last="Duong">Myngan Duong</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Nguyen, Tracy" sort="Nguyen, Tracy" uniqKey="Nguyen T" first="Tracy" last="Nguyen">Tracy Nguyen</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Schwarz, Nisha" sort="Schwarz, Nisha" uniqKey="Schwarz N" first="Nisha" last="Schwarz">Nisha Schwarz</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Fendler, Jessica" sort="Fendler, Jessica" uniqKey="Fendler J" first="Jessica" last="Fendler">Jessica Fendler</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Puri, Rishi" sort="Puri, Rishi" uniqKey="Puri R" first="Rishi" last="Puri">Rishi Puri</name><affiliation><nlm:aff id="aff2">Department of Cardiovascular Medicine,<institution>Cleveland Clinic</institution>,<addr-line>Cleveland, Ohio</addr-line>,<country>USA</country>;</nlm:aff></affiliation></author><author><name sortKey="Butters, Julie" sort="Butters, Julie" uniqKey="Butters J" first="Julie" last="Butters">Julie Butters</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author><author><name sortKey="Keyserling, Constance" sort="Keyserling, Constance" uniqKey="Keyserling C" first="Constance" last="Keyserling">Constance Keyserling</name><affiliation><nlm:aff id="aff3">Cerenis Therapeutics SA, Labege,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Paolini, John F" sort="Paolini, John F" uniqKey="Paolini J" first="John F." last="Paolini">John F. Paolini</name><affiliation><nlm:aff id="aff3">Cerenis Therapeutics SA, Labege,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Dasseux, Jean Louis" sort="Dasseux, Jean Louis" uniqKey="Dasseux J" first="Jean-Louis" last="Dasseux">Jean-Louis Dasseux</name><affiliation><nlm:aff id="aff3">Cerenis Therapeutics SA, Labege,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Nicholls, Stephen J" sort="Nicholls, Stephen J" uniqKey="Nicholls S" first="Stephen J." last="Nicholls">Stephen J. Nicholls</name><affiliation><nlm:aff id="aff1">South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</nlm:aff></affiliation></author></analytic><series><title level="j">Cardiovascular Diagnosis and Therapy</title><idno type="ISSN">2223-3652</idno><idno type="eISSN">2223-3660</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>CER-001 is an engineered pre-beta high-density lipoprotein (HDL) mimetic, which rapidly mobilizes cholesterol. Infusion of CER-001 3 mg/kg exhibited a potentially favorable effect on plaque burden in the CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis Regression) study. Since baseline atheroma burden has been shown as a determinant for the efficacy of HDL infusions, the degree of baseline atheroma burden might influence the effect of CER-001.</p></sec><sec><title>Methods</title><p>CHI-SQUARE compared the effect of 6 weekly infusions of CER-001 (3, 6 and 12 mg/kg) <italic>vs.</italic> placebo on coronary atherosclerosis in 369 patients with acute coronary syndrome (ACS) using serial intravascular ultrasound (IVUS). Baseline percent atheroma volume (B-PAV) cutoff associated with atheroma regression following CER-001 infusions was determined by receiver-operating characteristics curve analysis. 369 subjects were stratified according to the cutoff. The effect of CER-001 at different doses was compared to placebo in each group.</p></sec><sec><title>Results</title><p>A B-PAV ≥30% was the optimal cutoff associated with PAV regression following CER-001 infusions. CER-001 induced PAV regression in patients with B-PAV ≥30% but not in those with B-PAV <30% (−0.45%±2.65% <italic>vs.</italic> +0.34%±1.69%, P=0.01). Compared to placebo, the greatest PAV regression was observed with CER-001 3mg/kg in patients with B-PAV ≥30% (−0.96%±0.34% <italic>vs.</italic> −0.25%±0.31%, P=0.01), whereas there were no differences between placebo (+0.09%±0.36%) versus CER-001 in patients with B-PAV <30% (3 mg/kg; +0.41%±0.32%, P=0.39; 6 mg/kg; +0.27%±0.36%, P=0.76; 12 mg/kg; +0.32%±0.37%, P=0.97).</p></sec><sec><title>Conclusions</title><p>Infusions of CER-001 3 mg/kg induced the greatest atheroma regression in ACS patients with higher B-PAV. These findings identify ACS patients with more extensive disease as most likely to benefit from HDL mimetic therapy.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diagn Ther</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Diagn Ther</journal-id><journal-id journal-id-type="publisher-id">CDT</journal-id><journal-title-group><journal-title>Cardiovascular Diagnosis and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2223-3652</issn><issn pub-type="epub">2223-3660</issn><publisher><publisher-name>AME Publishing Company</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28567351</article-id><article-id pub-id-type="pmc">5440269</article-id><article-id pub-id-type="publisher-id">cdt-07-03-252</article-id><article-id pub-id-type="doi">10.21037/cdt.2017.02.01</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kataoka</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Andrews</surname><given-names>Jordan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Duong</surname><given-names>MyNgan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Tracy</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schwarz</surname><given-names>Nisha</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fendler</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Puri</surname><given-names>Rishi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Butters</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Keyserling</surname><given-names>Constance</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Paolini</surname><given-names>John F.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dasseux</surname><given-names>Jean-Louis</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Nicholls</surname><given-names>Stephen J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1</label>South Australian Health & Medical Research Institute,<institution>University of Adelaide</institution>,<addr-line>Adelaide</addr-line>,<country>Australia</country>;</aff><aff id="aff2"><label>2</label>Department of Cardiovascular Medicine,<institution>Cleveland Clinic</institution>,<addr-line>Cleveland, Ohio</addr-line>,<country>USA</country>;</aff><aff id="aff3"><label>3</label>Cerenis Therapeutics SA, Labege,<country>France</country></aff></contrib-group><author-notes><fn id="afn1"><p><italic>Contributions:</italic> (I) Conception and design: Y Kataoka, JF Paolini, JL Dasseux, SJ Nicholls; (II) Administrative support: J Andrews, J Butters, C Keyserling; (III) Provision of study materials or patients: J Andrews, C Keyserling, JF Paolini, SJ Nicholls; (IV) Collection and assembly of data: Y Kataoka, J Andrews, M Duong, T Nguyen, N Schwarz, J Fendler, R Puri, SJ Nicholls; (V) Data analysis and interpretation: Y Kataoka, SJ Nicholls; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.</p></fn><corresp id="cor1"><italic>Correspondence to:</italic> Stephen J. Nicholls, MBBS, PhD. South Australian Health & Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia. Email: <email xlink:href="stephen.nicholls@sahmri.com">stephen.nicholls@sahmri.com</email>.</corresp></author-notes><pub-date pub-type="epub-ppub"><month>6</month><year>2017</year></pub-date><pmc-comment>Fake ppub date generated by PMC from publisher
pub-date/@pub-type='epub-ppub' </pmc-comment>
<pub-date pub-type="ppub"><month>6</month><year>2017</year></pub-date><volume>7</volume><issue>3</issue><fpage>252</fpage><lpage>263</lpage><history><date date-type="received"><day>09</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>22</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>2017 Cardiovascular Diagnosis and Therapy. All rights reserved.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Cardiovascular Diagnosis and Therapy.</copyright-holder></permissions><abstract><sec><title>Background</title><p>CER-001 is an engineered pre-beta high-density lipoprotein (HDL) mimetic, which rapidly mobilizes cholesterol. Infusion of CER-001 3 mg/kg exhibited a potentially favorable effect on plaque burden in the CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis Regression) study. Since baseline atheroma burden has been shown as a determinant for the efficacy of HDL infusions, the degree of baseline atheroma burden might influence the effect of CER-001.</p></sec><sec><title>Methods</title><p>CHI-SQUARE compared the effect of 6 weekly infusions of CER-001 (3, 6 and 12 mg/kg) <italic>vs.</italic> placebo on coronary atherosclerosis in 369 patients with acute coronary syndrome (ACS) using serial intravascular ultrasound (IVUS). Baseline percent atheroma volume (B-PAV) cutoff associated with atheroma regression following CER-001 infusions was determined by receiver-operating characteristics curve analysis. 369 subjects were stratified according to the cutoff. The effect of CER-001 at different doses was compared to placebo in each group.</p></sec><sec><title>Results</title><p>A B-PAV ≥30% was the optimal cutoff associated with PAV regression following CER-001 infusions. CER-001 induced PAV regression in patients with B-PAV ≥30% but not in those with B-PAV <30% (−0.45%±2.65% <italic>vs.</italic> +0.34%±1.69%, P=0.01). Compared to placebo, the greatest PAV regression was observed with CER-001 3mg/kg in patients with B-PAV ≥30% (−0.96%±0.34% <italic>vs.</italic> −0.25%±0.31%, P=0.01), whereas there were no differences between placebo (+0.09%±0.36%) versus CER-001 in patients with B-PAV <30% (3 mg/kg; +0.41%±0.32%, P=0.39; 6 mg/kg; +0.27%±0.36%, P=0.76; 12 mg/kg; +0.32%±0.37%, P=0.97).</p></sec><sec><title>Conclusions</title><p>Infusions of CER-001 3 mg/kg induced the greatest atheroma regression in ACS patients with higher B-PAV. These findings identify ACS patients with more extensive disease as most likely to benefit from HDL mimetic therapy.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>High-density lipoprotein (HDL)</kwd><kwd>atheroma burden</kwd><kwd>regression</kwd><kwd>intravascular ultrasound (IVUS)</kwd><kwd>acute coronary syndrome (ACS)</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001824 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001824 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |